Left ventricular thrombus in patients with acute myocardial infarction: Case report and Caribbean focused update

CR Potu1,2, EE Tulloch-Reid1,2, DS Baugh1,2, EC Madu1,2

1. Department of Medicine, Division of Cardiovascular Medicine, Heart Institute of the Caribbean, Kingston, Jamaica
2. Center of Excellence for Cardiovascular Medicine and Sports Physiology, University of Technology, Kingston, Jamaica.

CASE REPORT


Corresponding Author:
Ernest C. Madu, MD, FACC, FRCP (Edin).
Division of Cardiovascular Medicine
Heart Institute of the Caribbean
23 Balmoral Avenue, Kingston 10, Jamaica.
Email: emadu@caribbeanheart.com

Abstract

Despite the well documented benefit of echocardiography in acute coronary syndromes, its wide-scale use in the Caribbean is limited by access, health literacy and affordability. Because of the limited use of echocardiography in the region, routine complications of acute myocardial infarction (AMI) are not fully appreciated and may go unrecognized, further contributing to increased cardiovascular morbidity and mortality. It is therefore necessary to bring focus to this common clinical condition and highlight the clinical utility of echocardiography in facilitating timely and accurate diagnosis. We report here a case of large left ventricular (LV) thrombus in a patient with AMI. Coronary angiography showed completely occluded left anterior descending artery (LAD) with angiographically normal remaining vessels. Immediate anticoagulation was commenced with heparin and overlapped with warfarin. No Primary Angioplasty (PA) was done based on the evidence from occluded artery trial. LV thrombus was completely resolved on echocardiography at three months. No evidence of thrombo-embolism was found during the resolution of LV thrombus.

Key Words
Myocardial infarction, LV thrombus, Echocardiography, Anticoagulation

Background
LV thrombus is a well recognized complication of AMI. It is estimated that 40-60% of patients with large anterior wall MI will develop a LV thrombus.1,2 Accurate and timely detection is important as it poses a high risk for thromboembolic events3,4 which can be prevented by systemic anticoagulation.5,6 Two-dimensional echocardiography has played a pivotal role in defining the natural history of thrombus formation in post MI patients. Risk factors for the development of LV thrombus include age, infarct location, infarct number, size and extent, and impairment in global or regional LV function (i.e. ejection fraction <40%). It occurs most commonly in anterior wall MI compared to non-anterior wall MI.7 We report here a case of large LV thrombus in a 61-year-old male with extensive anterior wall MI describing the diagnosis, therapeutic options, prognosis, and the practical strategies to prevent embolic complications.

Case details
A 61-year-old male patient with multiple risk factors for coronary artery disease was referred to our facility for echocardiography, three days after his admission to local public hospital for retrosternal chest pain. Even though the patient presented at the local public hospital within two hours of symptom onset and was at the time of presentation diagnosed (by 12 lead electrocardiogram and cardiac enzyme assay) with acute extensive anterior wall MI, thrombolytic therapy (TT) was not given and the patient was not referred for percutaneous intervention because these services were not available at the local public hospital. Attempted transfer to an affiliated tertiary hospital was unsuccessful due to bureaucratic and structural bottlenecks further delaying appropriate care with increasing morbidity and mortality risk for the patient. The patient was only transferred to our private facility after three days of delayed diagnostic testing and treatment. An echocardiogram was performed at our facility which demonstrated dilated LV with severely reduced systolic function.
function with an ejection fraction (EF) of 30-35%. Important regional wall motion abnormalities were present with akinesis of anteroseptal wall and LV apex, and severe hypokinesis of the lateral wall. Both findings were consistent with a recent extensive anterior wall MI. A large fresh apical thrombus was noted (Figure 1a) with spontaneous echo contrast, providing further evidence of low flow state. Coronary angiography (Figure 2) was recommended and performed on the same day which demonstrated complete occlusion of LAD at its origin but angiographically normal left main (LM), left circumflex (LCX) and dominant right coronary arteries (RCA) without any significant collateral circulation. The patient was then admitted to a private hospital and anticoagulation was initiated with low molecular weight heparin with a subcutaneous enoxaparin at a dose of 2mg/Kg given twice daily. Oral warfarin was started and antiplatelet agents were continued. A repeat echocardiogram was performed prior to discharge after seven days of overlap which confirmed a resolving thrombus and no evidence of new thrombus formation. He was discharged after we were satisfied that the repeated international normalised ratio (INR) values were within the therapeutic range (2-3). Dual antiplatelet therapy was also continued and his INR was carefully monitored as an outpatient. Repeat echocardiograms were performed at the follow-up visits at six weeks (Figure 1b) and three months (Figure 1c) after discharge. These showed complete resolution of the large apical thrombus at three months with no evidence of new thrombus formation. Warfarin therapy was continued for six months and then stopped.

**Discussion**

LV thrombus is a serious complication of AMI, with most thrombi developing during the first two weeks (median five to six days) after the initial AMI. In patients with extensive anterior wall MI, the development of thrombus may start as early as a few hours after MI evolving in to full blown thrombus by the third to fifth day. LV thrombus was diagnosed in our patient when the initial echocardiogram was undertaken (three days after presentation) and we are therefore uncertain as to when the thrombus first developed – it is possible that it was formed within the first 24 hours given the extensive transmural myocardial injury. While many patients will develop thrombosis while still hospitalised, it has been reported that patients with AMI may develop a new thrombus after the hospital discharge especially in patients with severe LV dysfunction and hence serial echocardiograms should be considered in such patients. The incidence of LV thrombus in the current era of reperfusion therapy is variable. Several studies have reported the decreased incidence of LV thrombus in patients treated with either TT9,10, or PA11,12 compared to those who did not receive reperfusion therapy. Vaitkus et al5 in a meta-analysis have reported the reduction in the incidence LV thrombus with TT, which however did not achieve statistical significance. Osherov et al,13 in a recent study compared the incidence of LV thrombus in patients treated with PA, TT and conservative therapy respectively, and reported that in the current era of rapid reperfusion by PA, the rate of thrombus formation is similar to that reported in the past and no difference was noted compared to those treated with either conservatively or thrombolysis.

Two-dimensional non-contrast transthoracic echocardiography (TTE) is the most commonly used technique for the clinical identification and follow-up of LV thrombus based on anatomical appearance. It has sensitivity and a specificity of 92–95% and 86–88% respectively for the diagnosis of LV thrombi.14,15

**Figures 1a-c: Echocardiogram showing the size of LV thrombus at third day, sixth week and end of third month after AMI. Arrows indicate LV thrombus.**
Despite the high accuracy it can be technically difficult in some patients because of the difficulty in discerning the myocardium-thrombus interface, limited near field resolution of the apex, or difficulty in obtaining images of the true apex. Recent studies have reported that up to two-thirds of LV thrombi can be missed by routine non-contrast echo, with mural or small thrombi least likely to be detected. Application of advanced echocardiographic techniques such as harmonic imaging and contrast echocardiography improves the diagnostic detection by improving the LV endocardial border definition, cavity delineation, and overall image quality and can be recommended. Recent advances in cardiac imaging have enabled assessment of vascular supply, allowing thrombi to be identified by avascular tissue characteristics rather than anatomical criteria resulting from absence of contrast uptake. Magnetic resonance imaging (MRI) with contrast enhancement has shown promise in the identification of LV thrombus, having greater sensitivity and specificity than TTE and trans-esophageal echocardiography (TEE). In particular, the delayed contrast-enhanced MRI technique using an inversion recovery pulse to suppress signal of normal myocardium has been shown to be highly beneficial in detecting intracavitary thrombi (which are dark), in addition to being an excellent technique for depicting adjacent MI and scarring. Weinsoft et al in a comparison study involving 121 patients using delayed contrast-enhanced MRI as a reference standard for detection of LV thrombus reported sensitivities of 33%, 61%, and 79% for echo, contrast echo and cine-CMR respectively.

LV thrombus increases the risk for embolic complications. The reported frequency of occurrence of stroke in patients with AMI is 1.5% to 3.6% which is thought to be embolic from a mural thrombus. Characteristics of thrombi that are associated with high risk for embolisation include mobility, protuberance, immaturity, filamentous nature, variable echo density with central liquefaction and irregular borders. Studies have shown that 55% of mobile thrombi and 45% of protruding thrombi embolize compared to 10% immobile and 7% non-protruding thrombi respectively.

In patients with LV thrombus or severe LV dysfunction complicating a recent MI, aggressive anti-thrombotic therapy with unfractionated or low molecular heparin should be immediately started and long term overlapped with warfarin. High dose intravenous heparin therapy with or without warfarin has been shown to be associated with reduction in the rate of thrombus formation and embolic phenomena during acute MI. Vaitkus et al. in a meta-analysis have shown that the administration of anticoagulation is associated with significant reduction in embolic events. ACC/AHA gave a class I recommendation that intravenous unfractioned heparin or low molecular weight heparin should be used in patients after ST-elevation MI who are at high risk for systemic emboli (occurrence of a large anterior infarction, documentation of thrombus in the LV by echocardiography, history of a previous embolic event, and atrial fibrillation). Treatment with warfarin without concomitant high dose heparin has been associated with high prevalence of LV thrombus and embolic complications. Kontny et al., in a study involving 229 patients, reported an increased prevalence of LV thrombus formation in patients treated with warfarin without concomitant high-dose heparin therapy and a similar but non-significant difference was observed in patients who were given low-dose heparin. The ability of warfarin to reduce the coagulation inhibitors (protein C and S) faster than the coagulation factors (Prothrombin-II) may result in a transient hypercoagulable state at the beginning of the therapy and hence it should ideally be overlapped with heparin to prevent thromboembolic complications. Once the therapeutic INR is reached heparin can be discontinued and oral anticoagulation continued for at least three to six months or indefinitely. Antiplatelet therapy has not been shown to be associated with reduced incidence of embolic complications.
The recommendation of TT for the treatment of LV thrombus is controversial. Available data is conflicting with a number of studies showing their beneficial effect and a number of other studies showing the contrary. Choice of thrombolytic agent did not have any impact on the LV thrombus formation. Moreover, TT can cause increased mobility of apical thrombus resulting in an increased tendency towards embolisation. Overall, no consensus has been achieved regarding the efficacy of TT for the treatment of LV thrombus. Thrombolysis or PA is undertaken with the primary goal of achieving coronary artery patency, which would be expected to prevent mural thrombi by preserving the viability of myocardium and preventing wall motion abnormalities. No TT was given during this patient’s stay in the local public hospital due to non-availability. The interventional cardiologists at the Heart Institute of the Caribbean (HIC) collectively made a decision not to attempt PA of the occluded infarct-related artery based on the evidence from occluded artery trial (OAT).

According to the OAT, late opening of the occluded infarct related artery (3–28 days after AMI) with percutaneous coronary intervention was not associated with any improved clinical end points (reduced occurrence of death, re-infarction or heart failure) and there was a trend toward excess re-infarction during a four-year follow-up period and hence it was not recommended in our patient. Repeat echocardiograms were done at six weeks and three months with the three-month study showing complete resolution of the thrombus. Although there is no consensus regarding the time intervals to perform the serial echocardiograms to avoid missing the diagnosis of late occurring LV thrombus, clinical judgment and consideration of other factors such as severity of AMI and LV dysfunction can be used to make the recommendation.

In summary LV thrombus should be suspected in patients with large anterior wall MI. If not recognised and treated immediately, it can result in life-threatening embolic complications. Echocardiogram is a simple, inexpensive and non-invasive technique that is crucial for immediate diagnosis. Effective measures should be taken by the various stakeholders to provide this necessary service in public hospitals or forge a meaningful partnership with better equipped private sector healthcare providers to make these services accessible to the population in a timely manner, thereby ensuring that patients receive evidence-based medicine that takes advantage of advances in medical knowledge and technology. This will facilitate a reduction in the social and economic burden of cardiovascular disease and mortality associated with the disease.

References


32. Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Ruzyllo W, Magnioni AP, White H,

ACKNOWLEDGEMENTS
We acknowledge and thank Ms. Theresa Lindo for her kind assistance in preparing the pictures.

PEER REVIEW
Not commissioned. Externally peer reviewed.

CONFLICTS OF INTEREST
The authors declare that they have no competing interests.

FUNDING
None

PATIENT CONSENT
The authors, CR Potu, DS Baugh, EE Tulloch-Reid, EC Madu declare that:

1. They have obtained written, informed consent for the publication of the details relating to the patient in this report.
2. All possible steps have been taken to safeguard the identity of the patient(s).
3. This submission is compliant with the requirements of local research ethics committees.